CAMP4 Therapeutics (NASDAQ:CAMP) Stock Rating Lowered by Zacks Research

CAMP4 Therapeutics (NASDAQ:CAMP) was downgraded by research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued to investors on Wednesday,Zacks.com reports.

A number of other equities research analysts also recently commented on CAMP. JPMorgan Chase & Co. upgraded CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $5.00 to $9.00 in a report on Tuesday, June 16th. Leerink Partners boosted their target price on CAMP4 Therapeutics from $8.00 to $9.00 and gave the stock an “outperform” rating in a research report on Thursday, April 2nd. Chardan Capital set a $6.50 price objective on shares of CAMP4 Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, June 10th. Weiss Ratings cut shares of CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, May 21st. Finally, Rodman & Renshaw initiated coverage on shares of CAMP4 Therapeutics in a report on Tuesday, April 14th. They issued a “buy” rating and a $7.00 target price on the stock. Seven investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat.com, CAMP4 Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $8.36.

CAMP4 Therapeutics Stock Performance

Shares of CAMP stock opened at $3.90 on Wednesday. The firm’s 50 day moving average price is $4.28 and its two-hundred day moving average price is $4.56. CAMP4 Therapeutics has a 52-week low of $1.32 and a 52-week high of $7.75. The stock has a market cap of $202.53 million, a PE ratio of -1.65 and a beta of 0.10.

CAMP4 Therapeutics (NASDAQ:CAMP) last issued its earnings results on Thursday, May 7th. The Wireless communications provider reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.11). The business had revenue of $1.29 million for the quarter. CAMP4 Therapeutics had a negative net margin of 2,193.72% and a negative return on equity of 194.74%. As a group, sell-side analysts predict that CAMP4 Therapeutics will post -0.84 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Vivo Capital LLC acquired a new position in shares of CAMP4 Therapeutics in the third quarter valued at approximately $11,765,000. Balyasny Asset Management L.P. acquired a new position in CAMP4 Therapeutics in the 4th quarter worth $14,938,000. Janus Henderson Group PLC increased its holdings in CAMP4 Therapeutics by 35.9% during the 4th quarter. Janus Henderson Group PLC now owns 6,307,636 shares of the Wireless communications provider’s stock worth $38,807,000 after purchasing an additional 1,666,666 shares in the last quarter. SummitTX Capital L.P. bought a new position in CAMP4 Therapeutics during the 1st quarter worth about $1,497,000. Finally, EcoR1 Capital LLC acquired a new stake in shares of CAMP4 Therapeutics in the 4th quarter valued at about $1,992,000.

CAMP4 Therapeutics Company Profile

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.